A robust blood gene expression-based prognostic model for castration-resistant prostate cancer

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Wang, Li ^a,b   Gong, Yixuan ^a   Chippada Venkata, Uma ^a   Heck, Matthias Michael ^c   Retz, Margitta ^c   Nawroth, Roman ^c   Galsky, Matthew ^a   Tsao, Che Kai ^a   Schadt, Eric ^a,b   de Bono, Johann ^d   Olmos, David ^e   Zhu, Jun ^a,b   Oh, William K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Genetics and Genomic Sciences ^*  (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TUMOR MARKER;

AGED; ARTICLE; BONE MARROW CELL; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; DOWN REGULATION; GENE EXPRESSION; GENOMICS; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; UPREGULATION; BLOOD; CANCER STAGING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; MIDDLE AGED; PROGNOSIS;

AGED; BIOMARKERS, TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RNA, MESSENGER;

EID: 84939549231     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0442-0     Document Type: Article

References (37)

1. Boyd L, Mao X, Lu Y-J. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012;9:652-64.
2. Twine N, Stover J, Marshall B, Dukart G, Hidalgo M, Stadler W, et al. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. 2003;63:6069-75.
3. Xu T, Shu C-T, Purdom E, Dang D, Ilsley D, Guo Y, et al. Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors. Cancer Res. 2004;64:3661-7.
4. Burczynski M, Twine N, Dukart G, Marshall B, Hidalgo M, Stadler W, et al. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res. 2005;11:1181-9.
5. Sharma P, Sahni N, Tibshirani R, Skaane P, Urdal P, Berghagen H, et al. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res. 2005;7:44.
6. Osman I, Bajorin D, Sun T-T, Zhong H, Douglas D, Scattergood J, et al. Novel blood biomarkers of human urinary bladder cancer. Clin Cancer Res. 2006;12:3374-80.
7. Critchley-Thorne R, Yan N, Nacu S, Weber J, Holmes S, Lee P. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007;4, e176.
8. Han M, Liew C, Zhang H, Chao S, Zheng R, Yip K, et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res. 2008;14:455-60.
9. Showe M, Vachani A, Kossenkov A, Yousef M, Nichols C, Nikonova E, et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res. 2009;69:9202-10.
10. Olmos D, Brewer D, Clark J, Danila D, Parker C, Attard G, et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol. 2012;13:1114-24.
11. Ross R, Galsky M, Scher H, Magidson J, Wassmann K, Lee G-SM, et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012;13:1105-13.
12. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002;62:4427-33.
13. Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Ser B (Stat Methodol). 2005;67:301-20.
14. Smyth GK. Limma: linear models for microarray data. New York: Springer; 2005. p. 397-420.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289-300.
16. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, et al. Genetics of gene expression and its effect on disease. Nature. 2008;452:423-8.
17. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580-5.
18. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
19. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov J. Molecular signatures database (MSigDB) 3.0. Bioinformatics (Oxford, England). 2011;27:1739-40.
20. Novershtern N, Subramanian A, Lawton L, Mak R, Haining W, McConkey M, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell. 2011;144:296-309.
21. Lazar C, Meganck S, Taminau J. Batch effect removal methods for microarray gene expression data integration: a survey. Brief Bioinform. 2012;14:469.
22. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A. 2001;98:31.
23. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, et al. Variations in DNA elucidate molecular networks that cause disease. Nature. 2008;452:429-35.
24. Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's Disease. Cell. 2013;153:707-20.
25. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:Article17.
26. Geman D, d'Avignon C, Naiman DQ. Classifying gene expression profiles from pairwise mRNA comparisons. Stat Appl Genet Mol Biol. 2004;3:Article19.
27. Tan AC, Naiman DQ, Xu L, Winslow RL. Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics. 2005;21:3896.
28. Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26:750.
29. Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014;12:317.
30. Templeton AJ, Pezaro C, Omlin A, McNamara MG. Simple prognostic score for metastatic castration resistant prostate cancer with incorporation of neutrophil to lymphocyte ratio. Cancer. 2014;120:3346.
31. Van Soest RJ, Templeton AJ. Neutrophil to lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data. Ann Oncol. 2015;26:743.
32. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411-25.
33. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739-52.
34. Tibshirani R. Regression shrinkage and selection via the lasso. J Royal Stat Soc Ser B (Stat Methodol). 1996;58:267-88.
35. de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302-9.
36. Halabi S, Lin CY, Kelly WK, Fizazi KS. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671.
37. Halabi S, Lin CY, Small EJ. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013;105:1729.